Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 315,520	$ 155,961
Accounts receivable, including related party amounts of $752 and $0 as of December 31, 2016 and 2015, respectively	3,157	339
Prepaid expenses and other current assets	1,511	540
Total current assets	320,188	156,840
Property and equipment, net	21,027	1,328
Intangible assets, net	399	454
Restricted cash	3,150	700
Other non-current assets	198	101
Total assets	344,962	159,423
Current liabilities:
Accounts payable	4,569	1,584
Accrued expenses, including related party amounts of $537 and $1,055 as of December 31, 2016 and 2015, respectively	16,320	8,430
Accrued tax liabilities	23	81
Deferred rent	1,027
Other current liabilities	59	60
Total current liabilities	21,998	10,155
Convertible loan, including accrued interest of $0 and $97 as of December 31, 2016 and 2015, respectively		38,336
Deferred revenue, including related party amounts of $527 and $0 as of December 31, 2016 and 2015, respectively	77,646	75,090
Deferred rent non-current	12,283	164
Other non-current liabilities	189	281
Total liabilities	112,116	124,026
Commitments and contingencies (Note 8)
Shareholders’ equity (deficit):
Common shares, CHF 0.03 par value, 40,253,674, and 5,528,079 shares authorized at December 31, 2016 and 2015, respectively, 40,164,307 and 5,528,079 shares issued at December 31, 2016 and 2015, respectively, 39,719,434, and 5,528,079 shares outstanding at December 31, 2016 and 2015, respectively, 15,325,607 and 2,444,364 shares in conditional capital at December 31, 2016 and 2015, respectively	1,216	181
Treasury shares, at cost, 444,873 shares and no shares at December 31, 2016 and 2015, respectively	0	0
Additional paid-in capital	288,739	4,636
Accumulated deficit	(57,083)	(33,906)
Accumulated other comprehensive loss	(26)	(8)
Total CRISPR Therapeutics AG shareholders’ equity (deficit)	232,846	(29,097)
Noncontrolling interest		(27)
Total shareholders’ equity (deficit)	232,846	(29,124)
Total liabilities, redeemable convertible preferred shares and shareholders’ equity (deficit)	$ 344,962	159,423
Series A-1 Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares		1,169
Series A-2 Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares		10,394
Series A-3 Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares		22,518
Series B Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares		$ 30,440